GLP-1 receptor agonists continue to demonstrate broad clinical utility in type 2 diabetes, with benefits that extend beyond glycemic control. A comprehensive umbrella review published in Diabetes, Obesity and Metabolism synthesized evidence from randomized controlled trials to characterize their effects across cardiovascular, renal, metabolic, and other major outcome domains.

The review incorporated 17 systematic meta-analyses encompassing 432 randomized trials and 65 unique outcomes. GLP-1 receptor agonist therapy was associated with reduced risks of heart failure (eOR 0.71, 95% CI 0.64–0.79) and peripheral artery disease (eOR 0.75, 95% CI 0.67–0.84). Drug-specific analyses identified significant cardiovascular risk reductions across agents, including liraglutide for major cardiovascular events (eOR 0.86, 95% CI 0.80–0.91), albiglutide for myocardial infarction (eOR 0.65, 95% CI 0.47–0.89), and dulaglutide for stroke (eOR 0.78, 95% CI 0.68–0.90).

Renal outcomes were similarly favorable. GLP-1 receptor agonist therapy lowered the risk of kidney-specific composite outcomes (eOR 0.76, 95% CI 0.66–0.87), nephropathy (eOR 0.74), and albuminuria (eOR 0.73). Clinical benefits extended to metabolic measures, including body weight reduction (eOR 0.46) and decreased glycated hemoglobin A1c (eOR 0.83). No material association with cancer risk was identified.

Gastrointestinal adverse events were consistently reported and represent the main safety consideration, including nausea (eOR 9.62), dyspepsia (eOR 4.85), and constipation (eOR 3.39). Overall, the findings support the use of GLP-1 receptor agonists for comprehensive cardiometabolic risk reduction in type 2 diabetes, with treatment selection requiring careful attention to individual tolerability.